Translational Development Acquisition Corp.

Translational Development Acquisition Corp. is a special purpose acquisition company with warrants listed under the ticker TDACW, oriented toward the life sciences and healthcare sector in keeping with its translational medicine mandate. The company submitted a Form 425 to the SEC on June 22, 2026, under accession number 0001193125-26-276612, a filing type required for written materials issued in connection with a proposed business combination, confirming the SPAC is in active deal proceedings. Sponsor identity and additional transaction details are available in the company's SEC filings. For comprehensive data on Translational Development Acquisition Corp., including its full filing history and combination status, sign up for access at SpacDesk.